Hepatitis C virus burden: Treating and educating people without prejudice

Table 2 Management and outcomes of anti-hepatitis C virus treatment

Treatment outcomes	n = 40
Therapy management
Self-administration at home, n (%)	16 (40.0)
Daily administration at the SUD, n (%)	21 (52.5)
In-patient in rehabilitation service, n (%)	3 (7.5)
Complete adherence to the programme, n (%)	37 (92.5)
Therapy completion, n (%)	40 (100)
Post-treatment controls, n (%)	37 (92.5)
HCV-RNA at end of treatment
Negative, n (%)	39 (97.5)
Not assessed, n (%)	1 (2.5)
SVR12	21 (52.5)
Negative, n (%)*	28 (70.0)
Not assessed, n (%)	12 (30.0)
Delayed SVR
Negative, n (%)1	9 (22.5)
Not assessed, n (%)	3 (7.5)
HCV reinfection, n (%)	1 (2.5)
Side effects, n (%)	0 (0)

¹Intention-to-treat analysis. SVR: Sustained Virologic response; HCV: Hepatitis C virus.